Oncology
Liver Cancer Is Moving Beyond TACE Alone
EMERALD-3 showed that adding the STRIDE immunotherapy regimen to TACE improved progression-free survival in embolization-eligible unresectable hepatocellular carcinoma. The result could shift practice, but the toxicity and implementation questions are not small.
China’s Biliary-Cancer Bet Has a Global Access Problem
A CE Mark Is Not Access
ALS Needs Proof, Not Just Another Biomarker
The Transplant Is Not the Finish Line
Chemo Shortages Are Back. So Is Rationing.
For Cancer That Reaches the CNS, a Payer Opens a Door
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
BRCA Care Cannot Start at Diagnosis
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.